Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Significant Decline in Short Interest

Fresenius SE & Co. (OTCMKTS:FSNUY) was the target of a significant decline in short interest during the month of October. As of October 30th, there was short interest totaling 53,811 shares, a decline of 85.3% from the October 15th total of 367,297 shares. Based on an average daily trading volume, of 166,740 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.0% of the shares of the company are sold short.

Fresenius SE & Co. Stock Performance

Shares of FSNUY stock traded up $0.07 during trading hours on Thursday, reaching $14.79. 47,884 shares of the company’s stock were exchanged, compared to its average volume of 166,257. Fresenius SE & Co. has a fifty-two week low of $10.33 and a fifty-two week high of $15.94. The stock has a market capitalization of $33.32 billion, a P/E ratio of 18.49 and a beta of 0.63. The business has a fifty day moving average price of $13.05 and a 200-day moving average price of $12.87. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.41.

Fresenius SE & Co. (OTCMKTS:FSNUY) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.03. Fresenius SE & Co. had a net margin of 6.58% and a return on equity of 10.24%. The business had revenue of $6.52 billion for the quarter, compared to the consensus estimate of $6.51 billion. Analysts predict that Fresenius SE & Co. will post 1.07 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on FSNUY. Citigroup reiterated a “buy” rating on shares of Fresenius SE & Co. in a report on Wednesday, October 28th. Deutsche Bank restated a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating. According to data from MarketBeat, the stock has an average rating of “Buy”.

Fresenius SE & Co. Company Profile

Fresenius SE & Co. KGaA is a German healthcare group headquartered in Bad Homburg. Its businesses include Fresenius Kabi, which supplies medicines, clinical nutrition, infusion therapies and medical technologies, and Fresenius Helios, which operates hospitals in Germany and Spain. Fresenius Kabi serves healthcare providers around the world, while Helios focuses on hospital and healthcare services in Europe. The group traces its origins to a pharmacy in Frankfurt acquired by pharmacist Eduard Fresenius in 1912.